Table 2 Baseline characteristics, treatment details, and follow-up of the study population
The details of patients before SBRT | Treatment protocols | Follow-up and review outcome | Survival outcome | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No | Gender | Age | AFP (ng/ml) | With virus hepatitis infection (B/C/None) | Child–Pugh Classification | ALBI grade | ECOG PS score | Previous treatments | Extrahepatic metastasis | Prescribed doses | Combination treatments | Other active lesions (time to progression) | Targeted lesion progression after SBRT (Y/N) | Follow-up period (months) | Living/dead | Cause of death |
1 | Male | 51 | 143 | Hepatitis B virus infection | A6 | 2 | 1 | Liver: TACE, Lenvatinib | 1. Lung 2.Mediastinal lymph node metastasis | 50 Gy/10fx | None | 1. Lung: Progression (uncontrolled) 2. Mediastinal lymph node metastasis: Progression (uncontrolled) 3. Liver: Progression (3 months) | N | 8 | Dead | Respiratory failure due to lung metastases |
2 | Male | 54 | 2837 | Hepatitis B virus infection | A6 | 2 | 1 | Liver: Hepatic Resection, Sorafenib | None | 45 Gy/9fx | None | Lung: New lesions (13 months) | N | 15 | Dead | Infectious shock due to hepatic failure |
3 | Male | 62 | 12 | Hepatitis B virus infection | B7 | 3 | 1 | Liver: Radiofrequency ablation, TACE | 1. Lung 2. Kidney | 49 Gy/7fx | None | 1. Lung: uncontrolled 2. Liver: progression (1 month) 3. Kidney: uncontrolled | Y | 6 | Dead | Hepatic encephalopathy due to hepatic failure |
4 | Male | 48 | 4856 | Hepatitis B virus infection | A6 | 2 | 1 | Liver: TACE | Retroperitoneal lymph node metastasis | 45 Gy/9fx | Sorafenib | 1.Retroperitoneal lymph node metastasis: uncontrolled 2. Liver: Progression (3 months) | N | 16 | Dead | Infectious shock due to hepatic failure |
5 | Male | 50 | 956 | Hepatitis B virus infection | A6 | 2 | 0 | Liver: Hepatic resection | None | 50 Gy/10fx | Lenvatinib | Liver: Progression (7 months) | N | 14 | Dead | Unknown causes |
6 | Female | 46 | 1517 | Hepatitis B virus infection | A6 | 2 | 0 | Liver: TACE | 1. Lung 2. Retroperitoneal lymph node metastasis | 50 Gy/10fx | None | 1. Lung: uncontrolled 2. Retroperitoneal lymph node metastasis: No change 3.Liver: Progression (1 months) | N | 9 | Dead | Infectious shock due to hepatic failure |
7 | Male | 47 | 29 | Hepatitis B virus infection | B7 | 3 | 1 | Liver: Radiofrequency ablation, TACE | 1. Lung 2. Intracranial metastases | 50 Gy/10fx | Lenvatinib | 1. Liver: uncontrolled 2. Lung: uncontrolled 3. intracranial metastases: uncontrolled | Y | 2 | Dead | Renal failure due to hepatic failure |
8 | Male | 45 | 189 | Hepatitis B virus infection | A5 | 1 | 0 | Liver: SBRT | Lung | 49 Gy/7fx | Sorafenib | 1. Lung (uncontrolled) 2. Bone: New lesions (9 months), with radiotherapy as additional treatment for pain relief | N | 17 | Dead | Respiratory failure due to lung metastases |
9 | Male | 69 | 1210 | Hepatitis B virus infection | A5 | 2 | 0 | Liver: SBRT, TACE | None | 49 Gy/7fx | Sorafenib | Lung: New lesions (21 months), with Lenvatinib and toripalimab as additional treatment | N | 52 | Dead | Infectious shock due to hepatic failure |
10 | Male | 58 | 2435 | Hepatitis B virus infection | A5 | 1 | 1 | Liver: Hepatic resection, Sorafenib | None | 50 Gy/10fx | Lenvatinib and toripalimab | Liver: Progression (1 months) | N | 45 | Dead | Upper gastrointestinal bleeding |
11 | Male | 32 | 323 | Hepatitis B virus infection | B7 | 2 | 1 | Liver: TACE, Sorafenib | Mesenteric lymph node metastasis | 49 Gy/7fx | Lenvatinib | 1. Mesenteric lymph node metastasis: uncontrolled 2. Liver: progression (1 month) | Y | 2 | Dead | Upper gastrointestinal bleeding |
12 | Female | 57 | 39,231 | Hepatitis B virus infection | B7 | 3 | 0 | Liver: TACE | Lung | 45 Gy/9fx | Toripalimab | Lung: New lesions (12 months) | N | 23 | Dead | Upper gastrointestinal bleeding |
13 | Male | 64 | 2139 | Hepatitis C virus infection | A6 | 2 | 1 | Liver: SBRT, TACE | Retroperitoneal lymph node metastasis | 45 Gy/9fx | Lenvatinib and toripalimab | Retroperitoneal lymph node metastasis: no change Liver: New lesion (12 months) | N | 21 | Dead | Upper gastrointestinal bleeding |
14 | Male | 48 | 176 | Hepatitis B virus infection | A6 | 2 | 1 | Liver: SBRT, TACE | None | 45 Gy/9fx | Toripalimab | Lung: New lesions (21 months) Liver: New lesion (15 months), add TACE | N | 21 | Living | |
15 | Female | 68 | 5679 | Hepatitis B virus infection | B7 | 3 | 0 | Liver: TACE | None | 50 Gy/10fx | Lenvatinib | Liver: Progression (5 months) Lung: New lesion (2 months), add toripalimab | N | 11 | Dead | Unknown causes |